A Research | Milton Maxwell

Agilent Technologies, Inc.

139.19

-1.41-1%

Dec 16, 4:00:02 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

FY Q1 '26

Reaffirms guide, details margin path

2/24/26Feb 24, 2026

Q&A largely reaffirmed the prepared script's upbeat tone on Q1's 4.4% core growth and FY26 guide, but surfaced margin cadence details: Q2 up 50bps YoY, accelerating H2 via volumes, Ignite savings, and tariff offsets. LDG's 3% growth missed slightly due to academia/government softness in cell analysis—yet management sees a bottom, with optimism from field feedback. CDMO hit low double-digits amid batch timing, still eyeing mid-teens FY. M&A discipline sharpened: high bar for multibillion deals, Ignite-proven integration via BIOVECTRA. Tariffs? No guide change. Funnels robust. Watch biotech funding conversion, A&G stability.

Key Stats

Market Cap

39.46B

P/E (TTM)

30.46

Basic EPS (TTM)

4.57

Dividend Yield

0.01%

Recent Filings

8-K

Controller retires January 2027

3/6/26Mar 6, 2026

Agilent's VP, Corporate Controller, and Principal Accounting Officer Rodney Gonsalves announced retirement effective January 2027, nearly a year after the March 5, 2026 notice. No disagreements on accounting or operations. Advance notice enables orderly search and transition.

10-Q

Q1 FY2026 results

3/3/26Mar 3, 2026

Agilent posted Q1 FY2026 revenue of $1,798M, up 7% y/y from $1,681M, fueled by 9% CrossLab growth to $758M and 7% Applied Markets gains to $361M, while Life Sciences rose 5% to $679M; yet operating income slipped 6% to $353M as gross margin narrowed to 52.6% from 53.5% on tariffs and mix, with $20M restructuring hitting SG&A. Diluted EPS of $1.07 tracks neatly to $305M net income over 284M shares. Cash dipped to $1,758M after $268M operating cash less $93M capex (FCF $175M derived), funding $152M buybacks and $72M dividends amid $3.4B debt and full revolver access. Tariffs sting now, but mitigation's underway. Strong recurring revenue endures. Competition sharpens in life sciences.

8-K

Agilent Q1 beats, raises FY26 guide

2/25/26Feb 25, 2026

Agilent kicked off FY26 with Q1 revenue of $1.80B, up 7.0% reported (4.4% core) despite a U.S. snowstorm hit. Non-GAAP EPS rose 4% to $1.36, fueled by CrossLab's 9% surge to $758M. It raised FY26 revenue to $7.3B-$7.5B and non-GAAP EPS to $5.90-$6.04. Weather disrupted; core momentum holds.

10-K

FY2025 results

12/22/25Dec 22, 2025

Agilent delivered FY2025 net revenue of $6.9B, up 7% y/y with no FX impact, rebounding from FY2024's 5% decline amid capital spending pressures. All segments grew, led by Life Sciences and Diagnostics Markets (+11%, BIOVECTRA adding 5 points) and CrossLab (+6%), while Applied Markets edged up 1%; Q4 momentum accelerated via pharma CDMO, LC/MS and services strength. Gross margins slipped 2 points to 52.4% from tariff/shipping hits and mix, yet operating income held at 21.3%. Cash swelled to $1.8B on $1.6B ops flow; $425M buybacks and $282M dividends continued. No FY2026 guidance disclosed. U.S. federal funding cuts threaten quarterly academic/gov momentum.

8-K

Agilent beats Q4, guides FY26 up

11/24/25Nov 24, 2025

Agilent crushed Q4 FY25 with $1.86B revenue, up 9.4% reported and 7.2% core, driven by 15% LDG growth while CrossLab and Applied ticked up 7% and 4%. GAAP EPS hit $1.53, non-GAAP $1.59. FY26 guides $7.3B-$7.4B revenue, $5.86-$6.00 non-GAAP EPS. Momentum builds.

About

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. This segment also offers GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies. The Diagnostics and Genomics segment provides genomics, contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses; and cell analysis plate based assays, flow cytometers, real-time cell analyzers, cell imaging systems, microplate readers, and related consumables. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

CEO

Mr. Padraig McDonnell

IPO

11/18/1999

Website

https://www.agilent.com

Employees

18,000

Sector

Healthcare

Industry

Diagnostics & Research